Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Lars Tatenhorst, Katrin Eckermann, Vivian Dambeck, et al.
Acta Neuropathologica Communications (2016) Vol. 4, Iss. 1
Open Access | Times Cited: 140

Showing 1-25 of 140 citing articles:

Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade
Masha G. Savelieff, Geewoo Nam, Juhye Kang, et al.
Chemical Reviews (2018) Vol. 119, Iss. 2, pp. 1221-1322
Closed Access | Times Cited: 479
Microglia jointly degrade fibrillar alpha-synuclein cargo by distribution through tunneling nanotubes
Hannah Scheiblich, Cira Dansokho, Dilek Mercan, et al.
Cell (2021) Vol. 184, Iss. 20, pp. 5089-5106.e21
Open Access | Times Cited: 237
ROCK inhibition in models of neurodegeneration and its potential for clinical translation
Jan Christoph Koch, Lars Tatenhorst, Anna‐Elisa Roser, et al.
Pharmacology & Therapeutics (2018) Vol. 189, pp. 1-21
Open Access | Times Cited: 190
Small molecule inhibits α-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons
Jordi Pujols, Samuel Peña‐Díaz, Diana F. Lázaro, et al.
Proceedings of the National Academy of Sciences (2018) Vol. 115, Iss. 41, pp. 10481-10486
Open Access | Times Cited: 189
Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson’s Disease
Yunna Li, Yun Xia, Sijia Yin, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 113
Molecular Basis of Small-Molecule Binding to α-Synuclein
Paul Robustelli, Alain Ibanez-de-Opakua, Cecily K. Campbell-Bezat, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 6, pp. 2501-2510
Open Access | Times Cited: 90
RhoA Signaling in Neurodegenerative Diseases
Sissel Ida Schmidt, Morten Blaabjerg, Kristine Freude, et al.
Cells (2022) Vol. 11, Iss. 9, pp. 1520-1520
Open Access | Times Cited: 74
ROCK inhibitors upregulate the neuroprotective Parkin-mediated mitophagy pathway
Natalia Moskal, Victoria Riccio, Mikhail Bashkurov, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 112
Intrinsically disordered proteins and biomolecular condensates as drug targets
Mateusz Biesaga, Marta Frigolé‐Vivas, Xavier Salvatella
Current Opinion in Chemical Biology (2021) Vol. 62, pp. 90-100
Open Access | Times Cited: 83
Small molecules targeting the disordered transactivation domain of the androgen receptor induce the formation of collapsed helical states
Jiaqi Zhu, Xavier Salvatella, Paul Robustelli
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 50
Development of Small Molecules Targeting α-Synuclein Aggregation: A Promising Strategy to Treat Parkinson’s Disease
Samuel Peña‐Díaz, Javier García‐Pardo, Salvador Ventura
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 839-839
Open Access | Times Cited: 27
Differentiable simulation to develop molecular dynamics force fields for disordered proteins
Joe G. Greener
Chemical Science (2024) Vol. 15, Iss. 13, pp. 4897-4909
Open Access | Times Cited: 13
Protocol for a randomized, placebo-controlled, double-blind phase IIa study of the safety, tolerability, and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with Parkinson’s disease (ROCK-PD)
Andreas Wolff, Helen Bidner, Yvonne Remane, et al.
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access | Times Cited: 8
SAFE-ROCK: A Phase I Trial of an Oral Application of the ROCK Inhibitor Fasudil to Assess Bioavailability, Safety, and Tolerability in Healthy Participants
Andreas Wolff, Jörg Peine, Josef Höfler, et al.
CNS Drugs (2024) Vol. 38, Iss. 4, pp. 291-302
Open Access | Times Cited: 8
Rho GTPases in Intellectual Disability: From Genetics to Therapeutic Opportunities
Valentina Zamboni, Rebecca Jones, Alessandro Umbach, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 6, pp. 1821-1821
Open Access | Times Cited: 75
Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson’s Disease and Amyotrophic Lateral Sclerosis
Anna‐Elisa Roser, Lars Tönges, Paul Lingor
Frontiers in Aging Neuroscience (2017) Vol. 9
Open Access | Times Cited: 66
Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against β-amyloid
Benjamin W. Henderson, Kelsey M. Greathouse, Raksha Ramdas, et al.
Science Signaling (2019) Vol. 12, Iss. 587
Open Access | Times Cited: 66
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Somin Kwon, Michiyo Iba, Changyoun Kim, et al.
Neurotherapeutics (2020) Vol. 17, Iss. 3, pp. 935-954
Open Access | Times Cited: 64
Rho-kinase ROCK inhibitors reduce oligomeric tau protein
Tadanori Hamano, Norimichi Shirafuji, Shu‐Hui Yen, et al.
Neurobiology of Aging (2019) Vol. 89, pp. 41-54
Open Access | Times Cited: 63
Targeting α-Synuclein for PD Therapeutics: A Pursuit on All Fronts
Margaux Teil, Marie-Laure Arotçarena, Emilie Faggiani, et al.
Biomolecules (2020) Vol. 10, Iss. 3, pp. 391-391
Open Access | Times Cited: 55
Targeting α‐synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease
Md. Ezazul Haque, Mahbuba Akther, Shofiul Azam, et al.
British Journal of Pharmacology (2021) Vol. 179, Iss. 1, pp. 23-45
Open Access | Times Cited: 51
Pharmacological Modulators of Small GTPases of Rho Family in Neurodegenerative Diseases
William Guiler, Addison Koehler, Christi Boykin, et al.
Frontiers in Cellular Neuroscience (2021) Vol. 15
Open Access | Times Cited: 42
Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases
Bao‐Guo Xiao, Cun‐Gen Ma, Qing Wang, et al.
Neural Regeneration Research (2022) Vol. 17, Iss. 12, pp. 2623-2623
Open Access | Times Cited: 31
CatWalk XT gait parameters: a review of reported parameters in pre-clinical studies of multiple central nervous system and peripheral nervous system disease models
Ivanna K. Timotius, Reinko F. Roelofs, Bar Richmond-Hacham, et al.
Frontiers in Behavioral Neuroscience (2023) Vol. 17
Open Access | Times Cited: 19
Microglia-mediated demyelination protects against CD8+ T cell-driven axon degeneration in mice carrying PLP defects
Janos Groh, Tassnim Abdelwahab, Yogita Kattimani, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top